A new clinical trial data describes the effect of dapagliflozin on the rate of kidney function decline in patients with chronic kidney disease.

TOP INSIGHT
Diabetes drug dapagliflozin slows kidney function decline in patients with chronic kidney disease, regardless of whether they have diabetes.
The key conclusion is that dapagliflozin is an effective treatment to slow progressive kidney function loss in patients with CKD with and without type 2 diabetes.
Therefore, in addition to reducing the risk of heart failure or mortality, as previously shown, dapagliflozin also slows the progression of kidney function decline.
Source-Medindia
MEDINDIA




Email










